Century Therapeutics, Inc. (IPSC) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
3675 Market Street
Philadelphia, PA 19104
United States of America (the)
Phone
267 817 5790
Website
Sector
Healthcare
Industry
Biotechnology
Employees
140
First IPO Date
June 18, 2021
| Name | Title | Pay | Year Born |
| Brent Pfeiffenberger | President, Chief Executive Officer & Chairman | 971,732 | 1978 |
| Chad A. Cowan | Chief Scientific Officer | 760,539 | 1972 |
| Gregory Russotti | Chief Technology & Manufacturing Officer | 789,960 | 1967 |
| Krista Kauppinen | VP, General Counsel & Head of Intellectual Property | 0 | N/A |
| Michael Naso | Senior Vice President of Cell Engineering | 0 | N/A |
| Megan Bilson | Chief People Officer | 0 | N/A |
| Douglas Carr | Senior VP of Finance & Operations, Principal Financial Officer and Secretary | 0 | N/A |
| Elizabeth Devlin | Vice President & Head of Development | 0 | N/A |
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.